TY - JOUR
T1 - Early gastric cancer detection in high-risk patients
T2 - A multicentre randomised controlled trial on the effect of second-generation narrow band imaging
AU - Yoshida, Naohiro
AU - Doyama, Hisashi
AU - Yano, Tomonori
AU - Horimatsu, Takahiro
AU - Uedo, Noriya
AU - Yamamoto, Yoshinobu
AU - Kakushima, Naomi
AU - Kanzaki, Hiromitsu
AU - Hori, Shinichiro
AU - Yao, Kenshi
AU - Oda, Ichiro
AU - Katada, Chikatoshi
AU - Yokoi, Chizu
AU - Ohata, Ken
AU - Yoshimura, Kenichi
AU - Ishikawa, Hideki
AU - Muto, Manabu
N1 - Funding Information:
Funding The Olympus Corporation provided partial funding for this study. This study was funded by joint research funds supplied by Kyoto University and the Olympus Corporation. Conflicts of interest exist between Kyoto University, but not the other participating institutions, and the Olympus Corporation.
Publisher Copyright:
©
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Objective Early detection of gastric cancer has been the topic of major efforts in high prevalence areas. Whether advanced imaging methods, such as second-generation narrow band imaging (2G-NBI) can improve early detection, is unknown. Design This open-label, randomised, controlled tandem trial was conducted in 13 hospitals. Patients at increased risk for gastric cancer were randomly assigned to primary white light imaging (WLI) followed by secondary 2G-NBI (WLI group: n=2258) and primary 2G-NBI followed by secondary WLI (2G-NBI group: n=2265) performed by the same examiner. Suspected early gastric cancer (EGC) lesions in both groups were biopsied. Primary endpoint was the rate of EGC patients in the primary examination. The main secondary endpoint was the positive predictive value (PPV) for EGC in suspicious lesions detected (primary examination). Results EGCs were found in 44 (1.9%) and 53 (2.3%; p=0.412) patients in the WLI and 2G-NBI groups, respectively, during primary EGD. In a post hoc analysis, the overall rate of lesions detected at the second examination was 25% (n=36/145), with no significant differences between groups. PPV for EGC in suspicious lesions was 13.5% and 20.9% in the WLI (50/371 target lesions) and 2G-NBI groups (59/282 target lesions), respectively (p=0.015). Conclusion The overall sensitivity of primary endoscopy for the detection of EGC in high-risk patients was only 75% and should be improved. 2G-NBI did not increase EGC detection rate over conventional WLI. The impact of a slightly better PPV of 2G-NBI has to be evaluated further. Trial registration number UMIN000014503.
AB - Objective Early detection of gastric cancer has been the topic of major efforts in high prevalence areas. Whether advanced imaging methods, such as second-generation narrow band imaging (2G-NBI) can improve early detection, is unknown. Design This open-label, randomised, controlled tandem trial was conducted in 13 hospitals. Patients at increased risk for gastric cancer were randomly assigned to primary white light imaging (WLI) followed by secondary 2G-NBI (WLI group: n=2258) and primary 2G-NBI followed by secondary WLI (2G-NBI group: n=2265) performed by the same examiner. Suspected early gastric cancer (EGC) lesions in both groups were biopsied. Primary endpoint was the rate of EGC patients in the primary examination. The main secondary endpoint was the positive predictive value (PPV) for EGC in suspicious lesions detected (primary examination). Results EGCs were found in 44 (1.9%) and 53 (2.3%; p=0.412) patients in the WLI and 2G-NBI groups, respectively, during primary EGD. In a post hoc analysis, the overall rate of lesions detected at the second examination was 25% (n=36/145), with no significant differences between groups. PPV for EGC in suspicious lesions was 13.5% and 20.9% in the WLI (50/371 target lesions) and 2G-NBI groups (59/282 target lesions), respectively (p=0.015). Conclusion The overall sensitivity of primary endoscopy for the detection of EGC in high-risk patients was only 75% and should be improved. 2G-NBI did not increase EGC detection rate over conventional WLI. The impact of a slightly better PPV of 2G-NBI has to be evaluated further. Trial registration number UMIN000014503.
KW - endoscopy
KW - gastric cancer
KW - screening
KW - surveillance
UR - http://www.scopus.com/inward/record.url?scp=85083206276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083206276&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2019-319631
DO - 10.1136/gutjnl-2019-319631
M3 - Article
C2 - 32241898
AN - SCOPUS:85083206276
SN - 0017-5749
VL - 70
SP - 67
EP - 75
JO - Gut
JF - Gut
IS - 1
ER -